Tags

Type your tag names separated by a space and hit enter

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.
J Am Acad Dermatol. 2012 Sep; 67(3):379-86.JA

Abstract

BACKGROUND

Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years.

OBJECTIVE

A secondary efficacy analysis was conducted to determine effects of finasteride (1 mg) on scalp hair growth in the 4 distinct scalp regions affected by male pattern hair loss.

METHODS

Multicenter, double-blind studies randomized patients with vertex hair loss (men aged 18-41 and 41-60 years) to finasteride (1 mg/d) or placebo. Efficacy was evaluated by review of standardized clinical photographs (global photographic assessment) of the vertex, anterior/mid scalp regions, and frontal and temporal hairlines over 24 months relative to baseline.

RESULTS

At 24 months, treatment with finasteride resulted in statistically significant (P ≤ .05) hair growth versus placebo in all scalp regions. There was also a significant decrease in hair loss in the younger men treated with finasteride in all areas, but only in the vertex and anterior/mid scalp regions in the older men. A slightly higher incidence of drug-related sexual adverse experiences was reported in the finasteride group than in the placebo group, irrespective of age.

LIMITATIONS

These studies enrolled men with vertex pattern hair loss; therefore, the findings may not be extrapolated to men with predominantly anterior/mid scalp, frontal, or temporal hair loss.

CONCLUSION

Based on global photographic assessment, finasteride (1 mg) is able to increase hair growth in all areas of the scalp affected by male pattern hair loss.

Authors+Show Affiliations

Duke University Medical Center, Durham, North Carolina, USA. olsen001@mc.duke.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22325459

Citation

Olsen, Elise A., et al. "Global Photographic Assessment of Men Aged 18 to 60 Years With Male Pattern Hair Loss Receiving Finasteride 1 Mg or Placebo." Journal of the American Academy of Dermatology, vol. 67, no. 3, 2012, pp. 379-86.
Olsen EA, Whiting DA, Savin R, et al. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol. 2012;67(3):379-86.
Olsen, E. A., Whiting, D. A., Savin, R., Rodgers, A., Johnson-Levonas, A. O., Round, E., Rotonda, J., & Kaufman, K. D. (2012). Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. Journal of the American Academy of Dermatology, 67(3), 379-86. https://doi.org/10.1016/j.jaad.2011.10.027
Olsen EA, et al. Global Photographic Assessment of Men Aged 18 to 60 Years With Male Pattern Hair Loss Receiving Finasteride 1 Mg or Placebo. J Am Acad Dermatol. 2012;67(3):379-86. PubMed PMID: 22325459.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. AU - Olsen,Elise A, AU - Whiting,David A, AU - Savin,Ronald, AU - Rodgers,Anthony, AU - Johnson-Levonas,Amy O, AU - Round,Elizabeth, AU - Rotonda,Jennifer, AU - Kaufman,Keith D, AU - ,, Y1 - 2012/02/09/ PY - 2011/08/09/received PY - 2011/10/18/revised PY - 2011/10/22/accepted PY - 2012/2/14/entrez PY - 2012/2/14/pubmed PY - 2012/12/10/medline SP - 379 EP - 86 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 67 IS - 3 N2 - BACKGROUND: Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years. OBJECTIVE: A secondary efficacy analysis was conducted to determine effects of finasteride (1 mg) on scalp hair growth in the 4 distinct scalp regions affected by male pattern hair loss. METHODS: Multicenter, double-blind studies randomized patients with vertex hair loss (men aged 18-41 and 41-60 years) to finasteride (1 mg/d) or placebo. Efficacy was evaluated by review of standardized clinical photographs (global photographic assessment) of the vertex, anterior/mid scalp regions, and frontal and temporal hairlines over 24 months relative to baseline. RESULTS: At 24 months, treatment with finasteride resulted in statistically significant (P ≤ .05) hair growth versus placebo in all scalp regions. There was also a significant decrease in hair loss in the younger men treated with finasteride in all areas, but only in the vertex and anterior/mid scalp regions in the older men. A slightly higher incidence of drug-related sexual adverse experiences was reported in the finasteride group than in the placebo group, irrespective of age. LIMITATIONS: These studies enrolled men with vertex pattern hair loss; therefore, the findings may not be extrapolated to men with predominantly anterior/mid scalp, frontal, or temporal hair loss. CONCLUSION: Based on global photographic assessment, finasteride (1 mg) is able to increase hair growth in all areas of the scalp affected by male pattern hair loss. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/22325459/Global_photographic_assessment_of_men_aged_18_to_60_years_with_male_pattern_hair_loss_receiving_finasteride_1_mg_or_placebo_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(11)01184-4 DB - PRIME DP - Unbound Medicine ER -